Some immune-suppressed states, for example infection with human immunodeficiency virus (HIV), can result in cytomegalovirus retinitis
Visual loss in patients with cytomegalovirus retinitis
and acquired immunodeficiency syndrome before widespread availability of highly active antiretroviral therapy.
Correlation between CD4+ counts and prevalence of cytomegalovirus retinitis
and human immunodeficiency virus-related noninfectious retinal vasculopathy in patients with acquired immunodeficiency syndrome.
Of 80 patients with newly diagnosed cytomegalovirus retinitis
who were randomized to receive induction therapy with oral valganciclovir--a prodrug that is rapidly hydrolyzed to ganciclovir--l0% experienced progression of the retinitis during the first 4 weeks of therapy, and 71.
Approved March 5, 1996 for the treatment of cytomegalovirus retinitis
in patients with AIDS.
Despite high unmet need, the market for the small molecules used to manage conditions such as genital and oral herpes, genital warts, cytomegalovirus retinitis
and pneumonia or shingles has been neglected compared with the successfully promoted immunizations for varicella in children, zoster in adults, or human papilloma virus in adolescents.
26, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "Global Cytomegalovirus Retinitis
Market 2014-2018" report to their offering.
3-7) Other infections that have been associated with IRIS events include varicella zoster, herpes simplex, meningeal cryptococcosis, hepatitis, cytomegalovirus retinitis
, progressive multifocal leuco-encephalopathy and intestinal parasites.
75, or more than 20 percent, on Friday, prompting a halt in trading, when it was disclosed that the company's drug Vistide, under review as a treatment to prevent blindness from cytomegalovirus retinitis
in AIDS patients, had caused tumors in female laboratory rats.
Vistide is an antiviral for the treatment of cytomegalovirus retinitis
in patients with AIDS.
Cidofovir and tenofovir are polar, acyclic nucleoside phosphonates that are FDA-approved as Vistide (cidofovir injection) for the treatment of cytomegalovirus retinitis
, and as Viread (tenofovir disoproxil fumarate) for the treatment of HIV.
Natural history and outcome of new AIDS-related cytomegalovirus retinitis
diagnosed in the era of highly active antiretroviral therapy.
These include Viread for the treatment of HIV, marketed exclusively by Gilead; Hepsera for the treatment of chronic hepatitis B, for which Gilead has retained rights in the United States, Canada, Europe, Australia and New Zealand and for which GlaxoSmithKline has licensed rights in Asia, Latin America and select other territories; Vistide(R) (cidofovir injection) for the treatment of cytomegalovirus retinitis
, marketed in the United States by Gilead and internationally by Pharmacia Corporation; and Tamiflu(R) (oseltamivir phosphate) for the treatment and prevention of influenza, marketed worldwide by Hoffmann-La Roche.